This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Novartis Ag. Active years: 2022-2026.
Company Filing History:
Years Active: 2022-2026
Title: Kirk Lee Clark: Innovator in Anti-Betacellulin Antibodies
Introduction
Kirk Lee Clark is a notable inventor based in Stow, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of anti-betacellulin antibodies. His work has implications for therapeutic applications, showcasing the potential of innovative antibody technologies.
Latest Patents
Kirk Lee Clark holds a patent for "Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules." This patent provides a comprehensive disclosure of anti-BTC antibodies, methods for producing these antibodies, and pharmaceutical compositions that include them. Additionally, the patent outlines methods for utilizing these antibodies and introduces multi-specific binding molecules, such as bispecific antibodies, which contain both a BTC binding moiety and an anti-VEGF binding moiety.
Career Highlights
Kirk Lee Clark is associated with Novartis AG, a leading global healthcare company. His role at Novartis has allowed him to work on cutting-edge research and development projects that aim to advance medical treatments and improve patient outcomes.
Collaborations
Kirk collaborates with talented professionals in his field, including Chad Eric Bigelow and Ana Maria Carrion. These collaborations enhance the innovative potential of their research and contribute to the advancement of biotechnology.
Conclusion
Kirk Lee Clark's contributions to the field of biotechnology, particularly through his patent on anti-betacellulin antibodies, highlight his role as an innovator. His work at Novartis AG and collaborations with other professionals further emphasize the importance of teamwork in driving scientific advancements.